EULAR 2022 Congress highlights
Expert video interviews from the EULAR 2022 Congress
07-06-2022 | EULAR 2022 | Conference coverage | Video
The BE COMPLETE and BE OPTIMAL trials of bimekizumab in PsA
Joseph Merola talks about the BE COMPLETE and BE OPTIMAL trials, which showed that the dual IL-17A/IL-17F inhibitor bimekizumab is a promising treatment option for psoriatic arthritis patients with and without prior exposure to TNF inhibitors.
Latest news from the EULAR 2022 Congress
Stay informed with Medicine Matters
Get the latest developments in rheumatology delivered straight to your inbox
Medicine Matters conference coverage is brought to you in partnership with medwireNews